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Summary
Background Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral 
antiangiogenic vascular endothelial growth factor receptor 1–3 inhibitor that has shown antitumour activity in recurrent 
ovarian cancer. We assessed eﬃ  cacy and safety of cediranib in combination with platinum-based chemotherapy and as 
continued maintenance treatment in patients with ﬁ rst relapse of platinum-sensitive ovarian cancer. 
Methods In this randomised, three-arm, double-blind, placebo-controlled phase 3 trial, we randomly assigned patients 
aged 18 years or older with relapsed platinum-sensitive ovarian cancer at 63 centres in Australia, Canada, New Zealand, 
Spain, and the UK. Participants received up to six cycles of platinum-based chemotherapy (once every 3 weeks) then 
entered a maintenance phase. Participants were randomly allocated (2:3:3), with ﬁ ve stratiﬁ cation factors and in 
alternating blocks, to receive placebo alongside chemotherapy and then placebo only maintenance (arm A; reference), 
cediranib 20 mg once-daily alongside chemotherapy then placebo only maintenance (arm B; concurrent), or cediranib 
20 mg once-daily alongside chemotherapy then cediranib 20 mg once-daily maintenance (arm C; maintenance). Patients 
continued treatment to progression or excessive toxic eﬀ ects. The primary eﬃ  cacy endpoint was progression-free survival 
between arms A and C. Eﬃ  cacy analysis was by intention to treat. Safety was assessed in all patients who received the 
allocated study drug. This trial is registered with ClinicalTrials.gov, number NCT00532194; the ISRCTN registry, 
number ISRCTN68510403; and ANZ Clinical Trials Registry, number ACTRN1261000016003.
Findings We randomly assigned 486 women between Nov 13, 2007, and Dec 23, 2011; results presented are for 
456 patients randomly assigned subsequent to the 30mg safety phase. During a median of 19·5 months (IQR 14–26) 
follow-up, 113 (96%) of 118 women assigned to arm A and 141 (86%) of 164 assigned to arm C had disease progression. 
Median progression-free survival was 11·0 months (95% CI 10·4–11·7) in arm C and 8·7 months (7·7–9·4) in arm A 
(hazard ratio 0·56, 0·44–0·72, p<0·0001). 156 (90%) of 174 patients in arm B had disease progression, and median 
progression-free survival was 9·9 months (95% CI 9·4–10·5). Diarrhoea, neutropenia, hypertension, and voice 
changes were signiﬁ cantly more common, during chemotherapy with cediranib, and diarrhoea, hypothyroidism and 
voice changes were more common during maintenance. Poor compliance with cediranib was noted during 
maintenance treatment with toxic eﬀ ects being the most common cause for discontinuation.
Interpretation Cediranib, when given orally with chemotherapy and continued as maintenance, yielded a meaningful 
improvement in progression-free survival in women with recurrent platinum-sensitive ovarian cancer, albeit with 
added toxic eﬀ ects. The positive results in ICON6 could provide women with a new therapeutic option for recurrent 
ovarian cancer. Assessment of the secondary endpoint of overall survival will need longer follow-up.
Funding Medical Research Council, Cancer Research UK, Canadian Cancer Society Research Institute, Cancer 
Australia, National Gynecological Cancer Centre, and AstraZeneca.
Copyright © Ledermann et al. Open Access article distributed under the terms of CC BY.
Introduction
Ovarian cancer, the leading cause of death from 
gynaecological tumours in high-income countries, 
initially responds well to surgery and platinum-based 
chemotherapy. Most patients develop recurrent treatable 
disease, albeit with diminishing beneﬁ t from each 
subsequent regimen.1 Although the cumulative eﬀ ect of 
successive lines of chemotherapy might be to extend 
survival, the duration of response shortens with each line 
of therapy, and the potential to increase the interval 
between treatments by using maintenance treatment to 
delay the need for further chemotherapy is deemed a 
clinically valuable research objective and beneﬁ cial for 
patients. One way of achieving this goal is to inhibit 
angiogenesis, the process of new blood vessel formation, 
which is needed for tumour growth.2 This approach has 
been validated through phase 3 trials with the monoclonal 
antibody to vascular endothelial growth factor (VEGF), 
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bevacizumab, which increases the response rate to 
chemotherapy3–5 and extends progression-free survival.3–6
Cediranib is an oral VEGF receptor (VEGFR 1–3) and 
c-Kit7 inhibitor that has shown antitumour activity in 
recurrent ovarian, colorectal, advanced biliary tract, 
renal, and lung cancers, and glioblastoma and alveolar 
soft-part sarcoma.8–14 On the basis of the phase 2 activity 
in ovarian cancer,8 we investigated the eﬃ  cacy and safety 
obtained by giving cediranib with chemotherapy and as 
maintenance treatment in patients with platinum-
sensitive15 ovarian cancer who had radiological evidence 
of recurrence more than 6 months after completion of 
ﬁ rst-line chemotherapy. The International Collaboration 
for Ovarian Neoplasia 6 (ICON6) trial was an investigator-
initiated, academically led trial developed through the 
Gynecologic Cancer InterGroup, and led by the Medical 
Research Council Clinical Trials Unit at University 
College London in the UK.
Methods
Study design and participants
We did an international, three-arm, randomised, double-
blind, placebo-controlled, phase 3 trial of cediranib in 
patients with relapsed platinum-sensitive ovarian cancer 
in 63 centres in Australia, Canada, New Zealand, Spain, 
and the UK. Participants were at least 18 years old and 
had CT or MRI evidence of recurrent ovarian, fallopian 
tube, or primary peritoneal cancer requiring further 
platinum-based chemotherapy at least 6 months after 
completing ﬁ rst-line chemotherapy. Patients had Eastern 
Cooperative Oncology Group (ECOG) performance 
status of 0 or 1 but were ineligible if they had poorly 
controlled hypertension, arterial thrombotic events 
within 12 months, substantial haemorrhage, or major 
surgery in the preceding 2 weeks before the start of 
treatment. Following ethical approval all patients 
provided written informed consent. The study protocol is 
available online.
Randomisation and masking
Patients were randomly assigned (2:3:3) to three parallel 
treatment arms: in arm A (reference) patients received 
platinum-based chemotherapy plus once-daily oral 
placebo tablets during the chemotherapy phase, then 
received placebo alone during the maintenance phase; in 
arm B (concurrent), patients received platinum-based 
chemotherapy plus once-daily oral cediranib, then 
switched to placebo during the maintenance phase; in 
arm C (concurrent plus maintenance), patients received 
once-daily oral cediranib during both phases.
Research in context
Evidence before this study
In 2003, we published the results of the International 
Collaborative for Ovarian Neoplasia (ICON) 4 trial in The Lancet, 
showing the value of platinum-combination treatment for 
women relapsing more than 6 months after completing ﬁ rst-
line treatment for ovarian cancer. This set a new standard of 
care with an improvement in overall survival, but the beneﬁ t 
was slight. In around 2006, unpublished data began to emerge 
showing that inhibitors of angiogenesis, blocking either the 
vascular endothelial growth factor (VEGF) ligand or its receptor 
could lead to shrinkage of ovarian tumours and delayed disease 
progression. We designed a three-arm, placebo-controlled, 
randomised trial (ICON6) in collaboration with the 
Gynaecological Cancer InterGroup adding the VEGF receptor 
tyrosine kinase inhibitor cediranib to chemotherapy and then 
continued as maintenance treatment. No previous trials of 
maintenance treatment with a molecularly targeted treatment 
in ovarian cancer had been done, although during this time, 
trials with the monoclonal antibody bevacizumab were in 
development for ﬁ rst-line treatment and for women with ﬁ rst 
relapse. ICON6 was an academic-led trial and complemented 
AstraZeneca-sponsored  or supported studies with cediranib 
(as cediranib was only available through the company) in lung 
and colon cancer and in glioblastoma. 
Added value of this study
In ICON6 we have shown that the addition of cediranib to 
platinum-based chemotherapy prolongs the progression-free 
survival of women with ovarian cancer. The three-arm trial 
shows an eﬀ ect of maintenance cediranib over and above the 
eﬀ ect of adding it to chemotherapy. The magnitude of beneﬁ t 
was similar to a trial with bevacizumab in a similar group of 
patients. Survival data are immature, but ICON6 is the ﬁ rst trial 
to show the beneﬁ t of a VEGF receptor tyrosine kinase inhibitor 
in recurrent ovarian cancer. Toxic eﬀ ects, particularly diarrhoea, 
fatigue, and hypertension, are problematic in some patients, 
and a proportion of the patients stopped the trial early because 
of side-eﬀ ects. However, the results of cediranib and 
bevacizumab trials show that antiangiogenic treatment is a 
new treatment option for women with relapsed ovarian cancer, 
and cediranib is the ﬁ rst oral drug to be beneﬁ cial in this setting.
Implications of all the available evidence
Development of treatments to prolong disease control of ovarian 
cancer is a key therapeutic aim. Trials of cediranib in other tumour 
types showed no evidence of a beneﬁ t, but the positive results in 
ICON6 have led the manufacturer to re-start development of 
cediranib in ovarian cancer. Another trial in the USA has shown 
that the addition of cediranib to the PARP inhibitor olaparib 
improves progression-free survival in a similar group of patients, 
further extending the potential of cediranib in this disease. The 
results of ICON6 have been shared with AstraZeneca who have 
now applied to the European Medicines Agency for market 
authorisation. A successful application will provide women with a 
new therapeutic option for recurrent ovarian cancer.
For more on the study protocol 
see http://www.icon6.org/
protocol/
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Randomisation was done centrally by a third party via an 
interactive voice and web response system. Permuted 
blocks were used (alternating between eight and 16) 
stratiﬁ ed by Gynecologic Cancer InterGroup, ﬁ rst-line 
chemotherapy (paclitaxel or other), relapse-free interval 
(6–12 months vs >12 months), planned chemotherapy 
regimen, and previous bevacizumab treatment. Both 
patients and the treating clinician were masked to the 
assigned treatment. Before the start of the trial, the 
Clinical Trials Unit tested samples of cediranib and 
matched placebo for eﬀ ectiveness of match with a panel 
of ﬁ ve testers. Samples were examined for colour, shape/
consistency, smell, and taste. No signiﬁ cant diﬀ erences 
were detected in any of the four features or overall 
between the cediranib and matched placebo
Procedures
Six cycles of chemotherapy (once every 3 weeks) were 
planned, but patients unable to complete six cycles and 
who were responding to treatment could begin 
maintenance treatment after at least four cycles were 
completed. Maintenance treatment for 18 months from 
initiation of all treatment for relapse was originally 
planned; however, a protocol modiﬁ cation in February, 
2010, allowed patients to continue masked treatment 
beyond 18 months to progression if they were thought to 
be still deriving clinical beneﬁ t by the treating clinician. 
Recommended chemotherapy was carboplatin with 
either paclitaxel or gemcitabine. Carboplatin mono-
therapy was permitted, as was cisplatin, if carboplatin 
could not be given.16,17 Protocol-deﬁ ned dose reductions 
of chemotherapy were done if necessary.
The trial drug, cediranib or placebo, was started with 
chemotherapy and continued to progression or excessive 
toxic eﬀ ects. An initial safety phase used a single daily 
dose of 30 mg. After review of the ﬁ rst 30 patients in 
November, 2008,18 the Independent Data Monitoring 
Committee recommended reduction of the dose of 
cediranib to 20 mg, in line with ongoing combination 
phase 3 trials in lung cancer, colorectal cancer, and 
glioblastoma,9,19,20 and continuation of the trial. Clinicians 
were provided with clinical management guidelines to 
help early management of the main toxic eﬀ ects 
of cediranib, which are hypertension, diarrhoea, 
proteinuria, and fatigue. Interruption of trial drug for up 
to 2 weeks as a result of toxic eﬀ ects was permitted to 
allow recovery to grade 1 or less. A dose reduction to 
15 mg was permitted, and needed for toxic eﬀ ects of 
grade 3 or more. Cediranib or placebo was discontinued 
permanently if gastrointestinal perforation, arterial 
thromboembolic events, grade 4 haemorrhage, hyper-
tensive crisis, or reversible posterior leuko encephalopathy 
syndrome occurred.
Baseline measurable disease was not needed. Tumour 
assessments were done by CT or MRI before treatment, 
at chemotherapy completion (week 18), and thereafter 
at weeks 52, 78, and when clinically needed. Patients 
were reviewed before each chemotherapy cycle and every 
6 weeks during maintenance treatment. Increasing 
CA-125 concentrations alone did not deﬁ ne progression, 
but could trigger unscheduled CT or MRI assessment to 
detect progression at any time (for full deﬁ nition of 
investigator-declared progression  see appendix). Patients 
were not unmasked on progression. 
Outcomes
ICON6 was originally planned with three stages: safety, 
eﬃ  cacy with a progression-free survival outcome using 
RECIST criteria,21 and a third expanded phase with 
overall survival as the primary outcome. We had to 
redesign the trial towards the end of the second phase 
because continuation to the third phase was not possible 
when AstraZeneca discontinued cediranib development 
in October, 2011, after disappointing outcomes in pivotal 
trials of other cancer types.9,12 The prospective analysis 
plan was modiﬁ ed (with no outcome analysis done) to 
account for shortage in future drug supply. The primary 
outcome changed to a progression-free survival 
Figure 1: Trial proﬁ le
SAE=serious adverse events. ITT=intention to treat. ECOG=Eastern Cooperative Oncology Group.
486 patients randomly assigned
115 received trial drug 171 received trial drug 158 received trial drug
456 randomly assigned
30 randomised to initial 30 mg 
 dose of cediranib and 
 excluded because of increased 
 toxic eﬀects
118 assigned to arm A  
 1 ineligible
 1 ECOG status not 0–1 
  and poor renal function
174 assigned to arm B 
 1 ineligible
 1 poor renal function
164 assigned to arm C
 6 ineligible
 1 ECOG status not 0–1 
 1 poor renal function 
 2 less than 2 week washout 
 1 CT scan out of date
 1 abnormal ECG
118 started chemotherapy phase
 117 completed at least one 
  cycle of chemotherapy
 93 completed six cycles of 
  chemotherapy
 1 SAE death
174 started chemotherapy phase
 174 completed at least one 
  cycle of chemotherapy
 142 completed six cycles of 
  chemotherapy
 2 SAE deaths
164 started chemotherapy phase
 164 completed at least one 
  cycle of chemotherapy
 130 completed six cycles of 
  chemotherapy
 1 SAE death
118 included in ITT analysis 174 included in ITT analysis 164 included in ITT analysis
85 started maintenance phase
 76 stopped trial drug due to 
  progression or death 
 9 stopped trial drug 
  because of other reasons
 1 SAE death
113 started maintenance phase
 93 stopped trial drug
  because of progression 
  or death 
 20 stopped trial drug
  because of other reasons
 1 SAE death
95 started maintenance phase
 67 stopped trial drug 
  because of progression 
  or death 
 28 stopped trial drug 
  because of other reasons
 1 SAE death
See Online for appendix
Articles
www.thelancet.com   Vol 387   March 12, 2016 1069
comparison between arms A and C, which was deemed 
most clinically relevant in view of emerging data for 
maintenance bevacizumab3,4,6. Progression-free survival 
was deﬁ ned as time from randomisation to disease 
progression or death from any cause (appendix).3,4,6 
Overall survival and comparison of progression-free 
survival in all three arms became secondary endpoints, 
along with assessment of toxicity and quality of life. The 
timeline for key milestones in the trial procedure, 
including the redesign, are outlined in the appendix. 
Toxicity was assessed locally by investigators and all 
adverse events were reported. 
Statistical analysis
After protocol amendment to the primary endpoint, the 
revised sample size needed 440 patients randomly 
assigned to receive cediranib 20 mg, excluding those 
who received 30 mg (see appendix for analysis of these 
patients). 176 events in arms A and C would provide at 
least 80% power to detect a progression-free survival 
hazard ratio (HR) of 0·65 with a 5% two-sided 
signiﬁ cance level. In October, 2012, the target number 
of events was imminent, but the statistical analysis plan 
was revised (with no outcome analysis having been 
done) because a substantial proportion of patients in 
arms B and C who were receiving treatment had not yet 
reached 18 months of treatment. As the primary 
analysis was between no cediranib (arm A) and a 
planned 18 months of cediranib (arm C), we deemed it 
wise to delay the analysis by a few months until an 
estimated 5% or less of patients were on cediranib or 
placebo.
Analyses were done on an intention-to-treat basis. 
Patients were censored at date of last follow-up if they 
had not progressed or died by the time of analysis. For 
the overall survival analysis, which included death from 
any cause, the date of censoring was brought forward to 
the data cutoﬀ  date for any patients who were conﬁ rmed 
to have been alive at a later date (appendix). Preliminary 
results were presented in 2013;22 the results presented 
here follow subsequent extensive data cleaning, although 
diﬀ erences are slight and detailed in the appendix. Other 
sensitivity analyses are also described (appendix).
The log-rank test was used as the primary test of an 
overall diﬀ erence between Kaplan-Meier curves for both 
progression-free survival and overall survival. A 
prespeciﬁ ed plan to address the proportionality of 
hazards was made because of the diﬃ  culty of 
interpreting the HR in the presence of time-dependent 
treatment eﬀ ects. The presence of non-proportional 
hazards was assessed with the Grambsch-Therneau 
test.23 With evidence of non-proportionality at the 5% 
level, survival data would be modelled by a ﬂ exible 
parametric model (3 degrees of freedom for the baseline 
hazard function, 1 degree of freedom for the time-
dependent treatment eﬀ ect) and diﬀ erences in restricted 
mean survival time would be estimated.24 Without 
evidence of non-proportional hazards, a standard Cox 
model would be used instead.
This trial is registered with ClinicalTrials.gov, number 
NCT00532194; the ISRCTN registry, number 
ISRCTN68510403; and ANZ Clinical Trials Registry, 
number ACTRN1261000016003.
Arm A 
(reference group; 
n=118)
Arm B 
(concurrent 
group; n=174)
Arm C 
(maintenance 
group; n=164)
Overall 
(n=456)
Age (years) 62
(53–67; 37–77)
62
(54–69; 30–85)
62
(54–68; 32–86)
62
(54–68; 30–86)
ECOG status
0 69 (58%) 109 (63%) 95 (58%) 273 (60%)
1 47 (40%) 64 (37%) 67 (41%) 178 (39%)
2 1 (1%) 0 0 1 (<1%)
3 0 0 1 (1%) 1 (<1%)
Not available 1 1 1 3 
Primary tumour type 
Ovary 98 (83%) 139 (80%) 131 (80%) 368 (81%)
Fallopian 1 (1%) 6 (3%) 6 (4%) 13 (3%)
Peritoneal 19 (16%) 29 (17%) 27 (16%) 75 (16%)
Histology
Serous 87 (74%) 129 (75%) 116 (71%) 332 (73%)
Endometrioid 3 (3%) 7 (4%) 9 (6%) 19 (4%)
Clear cell 3 (3%) 8 (5%) 5 (3%) 16 (4%)
Mucinous 0 3 (2%) 1 (1%) 4 (1%)
Mixed or other 21 (18%) 26 (15%) 30 (18%) 77 (17%)
Undiﬀ erentiated 3 (3%) 0 2 (1%) 5 (1%)
Not available 1 1 1 3
Tumour grade
Well diﬀ erentiated 1 (1%) 6 (4%) 5 (3%) 12 (3%)
Moderately diﬀ erentiated 18 (16%) 20 (13%) 24 (16%) 62 (15%)
Poorly diﬀ erentiated 97 (84%) 132 (84%) 117 (80%) 346 (82%)
Not assessable or missing 2 16 18 36
First-line chemotherapy included paclitaxel
Yes 104 (89%) 151 (88%) 149 (91%) 404 (89%)
No 13 (11%) 20 (12%) 15 (9%) 48 (11%)
Not available 1 3 0 4
Previous bevacizumab
Yes 6 (5%) 9 (5%) 9 (5%) 24 (5%)
No 112 (95%) 165 (95%) 155 (95%) 427 (95%)
Time since last chemotherapy
6–12 months 43 (36%) 59 (34%) 50 (30%) 152 (33%)
>12 months 75 (64%) 115 (66%) 114 (70%) 304 (67%)
Time from ﬁ rst histological 
diagnosis to randomisation 
(weeks)
82·6
(60–117; 29–449)
82·9
(64–135; 37–676)
87·4
(65–117; 45–369)
84·6
(62–123; 29–676)
Planned chemotherapy
Carboplatin alone 12 (10%) 19 (11%) 18 (11%) 49 (11%)
Carboplatin plus paclitaxel 89 (75%) 130 (75%) 121 (74%) 340 (75%)
Carboplatin plus 
gemcitabine
17 (14%) 25 (14%) 25 (15%) 67 (15%)
Data are median (IQR; range) or n (%). ECOG=Eastern Cooperative Oncology Group. 
Table 1: Baseline characteristics
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Role of the funding source
The funders of the study had no role in the study design, 
data collection (except for the collection of images for 
masked central imaging review), data analysis, data 
interpretation, or writing of the report. The 
corresponding author had full access to all the data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Recruitment of patients to ICON6 took place between 
Nov 13, 2007, and Dec 23, 2011, at 63 centres in the UK, 
Canada, Australia, New Zealand, and Spain. 486 patients 
were randomly assigned; however, the results presented 
here are for the 456 patients randomly assigned after the 
cediranib dose was reduced to 20 mg per day in November, 
2008 (30 patients were randomly assigned to receive 30 
mg cediranib, but then the trial was restarted at 20 mg 
because of toxicity and to bring it inline with other 
cediranib trials; ﬁ gure 1). Baseline characteristics were 
well balanced between groups (table 1). 22 (5%) patients 
had a second debulking attempt that was done before 
randomisation. No patients were lost to follow-up and 
ﬁ ve withdrew consent for collection of further data (one 
patient in arm A, one in arm B, and three in arm C).
Median follow-up was 19·5 months (IQR 14–26), during 
which 410 (90%) of the 456 patients had disease 
progression, including 113 (96%) of 118 patients in arm A, 
156 (90%) of 174 patients in arm B, and 141 (86%) of 
164 patients in arm C. Median progression-free survival 
was 11·0 months (95% CI 10·4–11·7) in arm C and 
8·7 months (7·7–9·4) in arm A (HR 0·56, 0·44–0·72, 
p<0·0001). 156 (90%) of 174 patients in arm B had disease 
progression, and median progression-free survival was 
9·9 months (9·4–10·5). Some evidence of non-proportional 
hazards was noted (p=0·06) and the restricted mean 
survival time over 2 years was 12·5 months (11·7–13·4) in 
arm C and 9·4 months (8·6–10·2) in arm A.
The diﬀ erence between groups in progression-free 
survival was statistically signiﬁ cant when arm B, 
concurrent cediranib, was included in the analysis 
(likelihood ratio ptrend<0·0001). For this secondary 
analysis, the median progression-free survival was 
9·9 months (9·4–10·5) and restricted mean survival time 
over 2 years was 11·0 months (10·4–11·5). Kaplan-Meier 
plots (ﬁ gure 2) seem to suggest similar survival in arms 
B and C during the chemotherapy phase when both 
groups were receiving cediranib, then worsening survival 
in arm B after the switch to placebo.
Overall survival data are immature because only 
236 (52%) of 456 of patients had died at data cutoﬀ 
(ﬁ gure 3). Median overall survival was 26·3 months 
(95% CI 23·8–30·0) in arm C and 21·0 months 
(17·7–27·6) in arm A (HR 0·77, 95% CI 0·55–1·07, 
p=0·11). We noted evidence of non-proportional hazards 
(p=0·001), and restricted mean survival time over 
3 years was 25·7 months (24·3–27·2) in arm C and 
22·8 months (20·7–24·8) in arm A (diﬀ erence 3 months, 
95% CI 0·3–5·7). The diﬀ erence in overall survival was 
non-signiﬁ cant (likelihood ratio trend p=0·3) across the 
three randomised arms, again with evidence of 
non-proportional hazards (p=0·005). An updated 
survival analysis with more mature data will be reported 
at a later stage.
About 80% of patients completed six cycles of 
chemotherapy in all arms (ﬁ gure 1). Treatment was not 
started in 12 patients (three in arm A, three in arm B, and 
six in arm C) who were thus excluded from the safety 
analysis.
Figure 2: Kaplan-Meier plot of progression-free survival over 2 years
Vertical reference line shows the median time to completion of the chemotherapy phase. Number at risk every 
6 months shown with the number of failure events in parentheses, after the time in which the number at risk was 
calculated. 
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Figure 3: Kaplan-Meier plot of overall survival over 3 years
Number at risk every 12 months shown with the number of failure events in parentheses, after the time in which 
the number at risk was calculated.
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149 (33%) of 456 patients discontinued treatment 
with cediranib or placebo early, before progressive 
disease or death occurred. Discontinuation before 
progression was more common with cediranib than 
placebo, most frequently for adverse events (table 2). 
Overall, drug discontinuation was high in all three 
arms excluding stopping due to progression or death 
(19 [17%] of 115 patients in arm A, 64 [37%] of 171 in 
arm B, and 76 [48%] of 158 in arm C). These 
discontinuations  were disproportionately higher in the 
two experimental arms despite provision of clinical 
guidelines for the management of cediranib toxic 
eﬀ ects. Most discontinuations also occurred while 
patients were still receiving chemotherapy: 14 (74%) of 
the 19 discontinuations in arm A, 53 (83%) of the 64 in 
arm B, and 56 (74%) of the 76 in arm C. Median time 
receiving cediranib or placebo was 8·0 months 
(5·1–11·0) in arm A, 7·4 months (2·6–10·8) in arm B, 
and 7·5 months (2·5–11·9) in arm C, and at time of 
analysis, 5% of patients continued unblinded on trial 
treatment. No dose reductions of cediranib or placebo 
occurred in arm A, but  14 (8%) of 171 patients in arm B 
and 21 (13%) of 158 patients in arm A and C received a 
reduced drug dose.
Adverse events, reported with Common Terminology 
Criteria for Adverse Events, are described separately for 
the chemotherapy phase, and for the maintenance phase 
when patients received cediranib or placebo without 
other treatment (table 3).
In line with previous early-phase studies of cediranib,8,9,13,19 
we noted an increased incidence of diarrhoea, neutropenia, 
hypertension, and voice changes, but not fatigue, nausea, 
or anorexia during chemotherapy in arms B and C 
compared with arm A. During cediranib maintenance 
treatment, an increased incidence of diarrhoea, 
hypothyroidism, and voice changes occurred, but not of 
hypertension because this seemed to be controlled after 
prompt management in the early chemotherapy phase. 
Four (3%) of 115 patients in arm A and 38 (12%) of 
329 patients in arms B and C had grade 3 or higher 
hypertension during chemotherapy, reducing to 8 (4%) of 
198 patients in arms A and B and 5 (5%) of 95 patients in 
arm C during maintenance (table 3). During chemotherapy, 
the most common adverse event was fatigue at any grade 
(412 [93%] of 444 patients), and diarrhoea at any grade was 
also common (350 [79%] of 444 patients; table 3).
Toxic eﬀ ects were reduced in the maintenance phase, 
with fatigue, diarrhoea, and nausea occurring most 
commonly. We noted diﬀ erences between arms A and B 
and arm C with diarrhoea, voice changes, and 
haemorrhage. Reports of toxic eﬀ ects in placebo 
treatment (arms A and B) were not uncommon.
A full analysis of quality-of-life data will be described 
elsewhere. The primary outcome compared global 
Arm A
(reference group)
Arm B
(concurrent group)
Arm C
(maintenance group)
Overall
Chemotherapy delivery
Overall 118 (100%) 174 (100%) 164 (100%) 456 (100%)
Six cycles completed 93 (79%) 142 (82%) 130 (79%) 365 (80%)
Four or ﬁ ve cycles 12 (10%) 14 (8%) 20 (12%) 46 (10%)
Fewer than four cycles 13 (11%) 18 (10%) 14 (9%) 45 (10%)
Trial drug discontinuation
Overall
N 115 (100%) 171 (100%) 158 (100%) 444 (100% )
Toxic eﬀ ects 14 (12%) 47 (27%) 62 (39%) 123 (28%)
Progression or death 90 (78%) 93 (54%) 70 (44%) 254 (57%)
Other reasons 5 (4%) 17 (10% ) 14 (9%) 36 (8%)
Chemotherapy phase
N 115 (100%) 171 (100%) 158 (100%) 444 (100%)
Toxic eﬀ ects 10 (7%) 39 (23%) 43 (27%) 92 (21%)
Progression or death 16 (14%) 5 (3%) 7 (4%) 28 (6%)
Other reasons 4 (3%) 14 (8%) 13 (8%) 31 (7%)
Maintenance phase
N 85 (100%) 113 (100%) 95 (100%) 293 (100%)
Toxic eﬀ ects 4 (5%) 8 (7%) 19 (20%) 31 (11%)
Progression or death 74 (87%) 88 (78%) 64 (67%) 226 (77%)
Other reasons 2 (2%) 6 (5%) 4 (4%) 12 (4%)
Chemotherapy delivery for all patients randomly assigned to the intention-to-treat analysis (n=456) and discontinuations of trial drug for patients included in the safety 
analysis (n=444). 2 patients in arm A, 7 in arm B, and 3 in arm C reported adverse events and disease progression as reasons for trial drug discontinuation, so for this table 
they were assigned as discontinuing because of toxic eﬀ ects.
Table 2: Chemotherapy delivery and trial drug discontinuation
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quality of life at 12 months between arms A and C, 
measured by the Quality of Life Questionnaire-C30 and 
adjusted for baseline value. 235 patients were in follow-up 
at 12 months and had quality-of-life data at baseline and 
12 months. Mean global quality of life was 4·5 points 
higher in arm C than in arm A, which is not a clinically 
or statistically signiﬁ cant diﬀ erence (p=0·2, although the 
95% CI of –2·0 to 11·0 includes a moderate diﬀ erence of 
10 points). We recorded no signiﬁ cant diﬀ erence between 
groups in each of three secondary hypotheses (appendix).
There was also no signiﬁ cant diﬀ erence between groups 
in each of three secondary hypotheses.
Discussion
This phase 3 trial showed that the addition of cediranib 
to platinum-based chemotherapy followed by 
maintenance cediranib in patients with recurrent 
platinum-sensitive ovarian cancer was associated with 
prolonged progression-free survival compared with 
chemotherapy alone. Bevacizumab studies also suggest 
that the greatest beneﬁ t of an antiangiogenic drug is 
achieved by adding it to chemotherapy and continuing 
the drug as a maintenance treatment.3,4,6 We were able to 
distinguish these two components in ICON6 to show 
that the greatest beneﬁ t was from concurrent plus 
maintenance treatment, whereas in the concurrent-only 
group, the early beneﬁ t of addition of cediranib to 
chemotherapy seemed to dissipate as patients switched 
to placebo maintenance.
The 8·7 month median progression-free survival in the 
reference group of ICON6 is consistent with other 
trials4,17,25 and the improvement in progression-free 
survival to a median of 11·0 months with maintenance 
cediranib is similar to that reported with bevacizumab 
maintenance after chemotherapy in a similar population.4,26
By comparison with intravenous bevacizumab, oral 
antiangiogenic drugs are easier to give, but have a 
diﬀ erent toxic proﬁ le of hypertension, fatigue, diarrhoea, 
and nausea.27 Prompt management of toxic eﬀ ects to 
restrict the number of patients needing a dose reduction 
or discontinuing cediranib is important and was helped 
by the inclusion of clinical management guidelines in 
ICON6. Planned chemotherapy cycles were not 
compromised by cediranib (80% of patients completing 
six cycles, consistent across groups); however, during the 
chemotherapy phase, 32% of patients in the two cediranib 
arms discontinued cediranib because of toxic eﬀ ects 
compared with 10% of those receiving placebo. In the 
maintenance phase, 10% of patients discontinued 
cediranib because of toxic eﬀ ects compared with 2% of 
those on placebo. Whether planned brief dose 
interruptions were suﬃ  ciently used is hard to tell and 
should be investigated in further studies as a strategy for 
managing discontinuations. From experience, treatment 
interruptions and prompt dose reductions have proved to 
be successful in other widely used tyrosine kinase 
inhibitors.28
The revised sample size, due to the shortage of 
cediranib supply, reduced the power to show a 
signiﬁ cant diﬀ erence in overall survival. A signiﬁ cant 
Chemotherapy phase (n=444) Maintenance phase (n=293)
Arm A: no cediranib 
(n=115)
Arms B plus C: 
cediranib (n=329)
Arms A plus B: no 
cediranib (n=198)
Arm C: cediranib 
(n=95)
Fatigue
Grade 1 or 2 96 (83%) 253 (77%) 155 (78%) 75 (79%)
Grade ≥3 9 (8%) 54 (16%) 2 (1%) 6 (6%)
Nausea or vomiting
Grade 1 or 2 81 (70%) 242 (74%) 87 (44%) 48 (51%)
Grade ≥3 7 (6%) 23 (7%) 8 (4%) 3 (3%)
Diarrhoea*
Grade 1 or 2 63 (55%) 251 (76%) 107 (54%) 76 (80%)
Grade 3 2 (2%) 34 (10%) 2 (1%) 10 (11%)
Grade 4 0 0 0 1 (1%)
Hypertension†
Grade 1 or 2 38 (33%) 148 (45%) 59 (30%) 33 (35%)
Grade 3 4 (3%) 38 (12%) 8 (4%) 5 (5%)
Grade 4 or 5 0 0 0 0
Hypothyroidism
Grade 1 or 2 9 (8%) 36 (11%) 18 (9%) 24 (25%)
Grade ≥3 0 0 1 (<1%) 0
Febrile neutropenia
Grade 1 or 2 1 (1%) 3 (1%) 1 (1%) 1 (1%)
Grade ≥3 4 (3%) 22 (7%) 0 1 (1%)
Neutropenia
Grade 1 or 2 28 (24%) 141 (43%) 52 (26%) 22 (23%)
Grade ≥3 27 (23%) 85 (26%) 13 (7%) 6 (6%)
Thrombocytopenia
Grade 1 or 2 36 (31%) 129 (39%) 35 (18%) 18 (19%)
Grade ≥3 3 (3%) 25 (8%) 4 (2%) 2 (2%)
Proteinuria
Grade 1 or 2 11 (10%) 55 (17%) 21 (11%) 16 (17%)
Grade ≥3 0 2 (1%) 0 0
Voice changes
Grade 1 or 2 7 (6%) 77 (23%) 14 (7%) 24 (25%)
Grade ≥3 0 1 (<1%) 0 0
Thrombosis or embolism
Grade 1 or 2 0 6 (2%) 1 (<1%) 2 (2%)
Grade ≥3 1 (1%) 10 (3%) 1 (<1%) 3 (3%)
Haemorrhage or bleeding
Grade 1 or 2 15 (13%) 79 (24%) 14 (7%) 15 (16%)
Grade ≥3 0 0 0 0
CNS cerebrovascular ischaemia 
Grade 1 or 2 0 1 (<1%) 0 0
Grade ≥3 0 5 (2%) 0 1 (1%)
Summary of adverse events as maximum grade reported by phase of trial in safety analysis patients (n=444). Groups 
are split into cediranib-containing and non-cediranib-containing arms according to the phase of the trial. Seven grade 
5 serious adverse events occurred: pneumonia and somnolence in arm A; pneumonia, gastrointestinal perforation, and 
cardiac ischaemia in arm B; and pancreatitis and hypoxia in arm C. *Diarrhoea seems to be the only toxic eﬀ ect that 
could have a carryover eﬀ ect into the maintenance phase, with arm B having greater grade 1 and 2 levels than arm A. 
†No grade 4 or 5 hypertension (hypertensive crisis or death).
 Table 3: Adverse events
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survival diﬀ erence has not been noted with any 
antiangiogenic drug trials in recurrent ovarian cancer. 
In ICON6, a 5·3 month diﬀ erence in median overall 
survival was reported between reference and 
maintenance cediranib arms. With a 3-year restricted 
mean survival time analysis, the overall survival 
diﬀ erence was 3 months. However, the ICON6 overall 
survival analysis was done when only 52% of expected 
deaths had occurred and it will be assessed again when 
more than 80% of deaths have occurred, although 
because of the small sample size, the power to detect a 
realistic diﬀ erence will be restricted.
In absolute terms, survival in all groups was somewhat 
shorter than reported in other trials of combination 
therapy in recurrent ovarian cancer, with or without 
maintenance treatment.4,25 This probably reﬂ ects 
diﬀ erences between trial cohorts in timing of initiation 
of second-line treatment, because the median duration of 
survival as measured from the time of original diagnosis, 
46 months with cediranib, compares favourably with 
other trials.
The improvement in time to progression seen with the 
combination of cediranib and chemotherapy, followed by 
maintenance cediranib, represents a clinically relevant 
prolongation in progression-free survival for patients 
with recurrent ovarian cancer and is in line with other 
VEGF maintenance trials.4 Two other oral VEGFR 
inhibitors, pazopanib and nintedanib,29,30 have shown 
slight improvements in progression-free survival in ﬁ rst-
line treatment of ovarian cancer. However, toxic eﬀ ects of 
cediranib and other VEFR inhibitors can be problematic29 
and need careful management. The three-arm ICON6 
trial has shown that the beneﬁ t in progression-free 
survival with cediranib is derived from continuing 
cediranib as a maintenance treatment after chemotherapy. 
Cediranib is a new treatment option that should be 
considered for the treatment of patients with 
platinum-sensitive recurrent ovarian cancer.
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